Related Experiment Video

Updated: Jul 26, 2026

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
07:56

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

Reversal of resistance in multidrug resistance protein (MRP1)-overexpressing cells by LY329146

B H Norman1, A H Dantzig, J S Kroin

  • 1Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.

Bioorganic & Medicinal Chemistry Letters
|December 28, 1999
PubMed

Insights

The benzothiophene LY329146 drug overcomes multidrug resistance protein 1 (MRP1) mediated drug efflux. This compound reverses resistance to chemotherapy drugs like doxorubicin and vincristine in cancer cells.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Oncology

Background:

  • Multidrug resistance protein 1 (MRP1) is a key transporter involved in cancer drug resistance.
  • Overexpression of MRP1 leads to reduced intracellular accumulation of various chemotherapeutic agents.
  • Targeting MRP1 is a promising strategy to overcome multidrug resistance in cancer therapy.

Purpose of the Study:

  • To investigate the potential of benzothiophene LY329146 as an inhibitor of MRP1.
  • To evaluate the ability of LY329146 to reverse the drug-resistant phenotype in MRP1-overexpressing cells.
  • To assess the effect of LY329146 on MRP1-mediated substrate transport.

Main Methods:

  • Cell culture of MRP1-overexpressing cells.
  • Combination treatment with LY329146 and MRP1-associated oncolytics (doxorubicin, vincristine).
  • In vitro transport assays using membrane vesicles and the MRP1 substrate LTC4.

Main Results:

  • LY329146 reversed the drug resistance phenotype in MRP1-overexpressing cells when combined with doxorubicin and vincristine.
  • LY329146 demonstrated inhibition of MRP1-mediated LTC4 uptake in membrane vesicle assays.
  • These findings suggest LY329146 acts as an MRP1 inhibitor.

Conclusions:

  • Benzothiophene LY329146 is a potent inhibitor of MRP1.
  • LY329146 can overcome MRP1-mediated drug resistance in cancer cells.
  • LY329146 represents a potential therapeutic agent for combination therapy in MRP1-overexpressing cancers.

More Related Videos

Expression, Detergent Solubilization, and Purification of a Membrane Transporter, the MexB Multidrug Resistance Protein10:43

Expression, Detergent Solubilization, and Purification of a Membrane Transporter, the MexB Multidrug Resistance Protein

Published on: December 3, 2010

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...